Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis

Osteoarthritis: A Companion to Rheumatology

Volumn , Issue , 2007, Pages 178-201

  Solomon, Daniel H ^a,b   Goodson, Nicola J ^c,d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

^d University Hospital Aintree   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882481043     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-323-03929-1.50016-1     Document Type: Chapter

References (113)

1. Moreland LW, Russell AS, Paulus HE Management of rheumatoid arthritis: The historical context. J Rheumatol 2001, 50:1431-1452.
2. Simmons DL, Botting RM, Hla T Cyclooxygenase isozymes: The biology of prostaglandin synthesis and inhibition. Pharmacological Reviews 2004, 56(3):387-437.
3. FitzGerald GA, Patrono C The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001, 345(6):433-442.
4. Simmons DL, Botting RM, Hla T Cyclooxygenase isozymes: The biology of prostaglandin synthesis and inhibition. Pharmacological Reviews 2004, 56(3):387-437.
5. Brune K, Hinz B Selective cyclooxygenase-2 inhibitors: Similarities and differences. Scand J Rheumatol 2004, 33(1):1-6.
6. Bombardieri S, Cattani P, Ciabattoni G, Di Munno O, Pasero G, Patrono C, et al. The synovial prostaglandin system in chronic inflammatory arthritis: Differential effects of steroidal and nonsteroidal anti-inflammatory drugs. Br J Pharmacol 1981, 73(4):893-901.
7. Simmons DL, Botting RM, Hla T Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacological Reviews 2004, 56(3):387-437.
8. Wallace JR, McKnight W, Reuter BK, Vergnolle N NSAID induced gastric damage in rats: Requirements for inhibition of both cyclooxygenase 1 and 2. Gastroenterology 2000, 119:706-714.
9. Solomon LM, Juhlin L Prostaglandins on cutaneous vasculature. J Invest Dermatol 1968, 51:280-282.
10. Jaffe EA, Weksler B Recovery of endothelial cell prostacyclin production after inhibition by low doses of aspirin. J Clin Invest 1979, 63:532-535.
11. Simmons DL, Botting RM, Hla T Cyclooxygenase isozymes: The biology of prostaglandin synthesis and inhibition. Pharmacological Reviews 2004, 56(3):387-437.
12. Peplow PV Properties and actions of non-steroidal antiinflammatory drugs, including their effects on prostaglandin and macromolecular biosynthesis. Prostaglandins Leukotrienes & Essential Fatty Acids 1988, 33(3):239-252.
13. Patrignani P, Sciulli MG Pharmaceutical exploitation: Cyclooxygenase and lipooxygenase inhibitors. The Eicosenoids. 2004, 599-612. John Wiley & Sons, Cambridge. C.-P. P (Ed.).
14. Davies NM, Skjodt N Choosing the right NSAID. Clin Pharmacokin 2000, 38(5):377-392.
15. Day RO, Mclachlan AJ, Graham GG, Williams KM Pharmacokinetics of nonsteroidal anti-inflammatory drugs in synovial fluid. Clin Pharmacokinet 1999, 36(3):191.
16. FitzGerald GA, Patrono C The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001, 345(6):433-442.
17. Bradley JD, Brandt KD, Katz BP, Kalasinski LA, Ryan SI Comparison of an anti-inflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee. N Engl J Med 1991, 11(325):87-91.
18. Pincus T, Koch GG, Sokka T A randomized, double-blind, crossover clinical trial of diclofenac plus misoprostol versus acetaminophen in patients with osteoarthritis of the hip or knee. Arthritis Rheum 2001, 44:1587-1598.
19. Geba GP, Weaver AL, Polis AB, Dixon ME, Schnitzer TJ Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: A randomized trial. JAMA 2002, 287:64-71.
20. Case JP, Baliunas AJ Block JA. Lack of efficacy of acetaminophen in treating symptomatic knee osteoarthritis: A randomized, double-blind, placebo-controlled comparison trial with diclofenac sodium. Arch Intern Med 2003, 163:169-178.
21. Boureau F, Schneid H, Zeghari N, Wall R, Bourgeois P The IPSO study: Ibuprofen, paracetamol study in osteoarthritis. A randomised comparative clinical study comparing the efficacy and safety of ibuprofen and paracetamol analgesic treatment of osteoarthritis of the knee or hip. Ann Rheum Dis 2004, 63:1028-1034.
22. Pincus T, Koch G, Lei H, Mangal B, Sokka T, Moskowitz R, et al. Patient preference for placebo, acetaminophen (paracetamol) or celecoxib efficacy studies (PACES): Two randomised, double blind, placebo controlled, crossover clinical trials in patients with knee or hip osteoarthritis. Ann Rheum Dis 2004, 63:931-939.
23. March L, Irwig L, Schwarz J, Simpson J, Chock C, Brooks P N of 1 trials comparing a non-steroidal anti-inflammatory drug with paracetamol in osteoarthritis. BMJ 1994, 309:1041-1045.
24. Schnitzer TJ, Kamin M, Olson WH Tramadol allows reduction of naproxen dose among patients with naproxen-responsive osteoarthritis pain: A randomized, double-blind, placebocontrolled study. Arthritis Rheum 1999, 42:1370-1377.
25. Caldwell JR, Hale ME, Boyd RE, Hague JM, Iwan T, Shi M, et al. Treatment of osteoarthritis pain with controlled release oxycodone or fixed combination oxycodone plus acetaminophen added to nonsteroidal antiinflammatory drugs: A double blind, randomized, multicenter, placebo controlled trial. J Rheumatol 1999, 26:862-869.
26. Wilder-Smith CH, Hill L, Spargo K, Kalla A Treatment of severe pain from osteoarthritis with slow-release tramadol or dihydrocodeine in combination with NSAIDs: A randomised study comparing analgesia, antinociception and gastrointestinal effects. Pain 2001, 91:23-31.
27. Emkey R, Rosenthal N, Wu SC, Jordan D, Kamin M CAPSS-114 Study Group. Efficacy and safety of tramadol/acetaminophen tablets (ultracet) as add-on therapy for osteoarthritis pain in subjects receiving a COX-2 nonsteroidal antiinflammatory drug: A multicenter, randomized, double-blind, placebo-controlled trial. J Rheumatol 2004, 31:150-156.
28. Mason L, Moore RA, Edwards JE, Derry S, McQuay HJ Topical NSAIDs for chronic musculoskeletal pain: Systematic review and meta-analysis. BMC Musculoskeletal Disorders 2004, 5:28.
29. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines Recommendations for the medical management of osteoarthritis of the hip and knee. Arthritis Rheum 2000, 43:1905-1915.
30. Zhang W, Doherty M, Arden N, Bannwarth B, Bijlsma J, Gunther KP, et al. EULAR evidence based recommendations for the management of hip osteoarthritis: Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2005, 64:669-681.
31. Saag KG, Olivieri JJ, Patino F, Mikuls TR, Allison JJ, MacLean CH Measuring quality in arthritis care: The Arthritis Foundation's quality indicator set for analgesics. Arthritis Rheum 2004, 51:337-349.
32. Accessed 22 July 2005 . http://www.fda.gov/medwatch/SAFETY/2004/jan_PI/Celebrex_PLpdf.
33. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis: VIGOR Study Group. N Engl J Med 2000, 343:1520-1528.
34. Ofman JJ, MacLean CH, Straus WL, Morton SC, Berger ML, Roth EA, et al. A metaanalysis of severe upper gastrointestinal complications of nonsteroidal antiinflammatory drugs. J Rheumatol 2002, 29:804-812.
35. Bollini P, Garcia Rodriguez LA, Perez Gutthann S, Walker AM The impact of research quality and study design on epidemiologic estimates of the effect of nonsteroidal anti-inflammatory drugs on upper gastrointestinal tract disease. Arch Intern Med 1992, 152:1289-1295.
36. Gabriel SE, Jaakkimainen L, Bombardier C Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs: A meta-analysis. Ann Intern Med 1991, 115:787-796.
37. Hernandez-Diaz S, Rodriguez LA Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: An overview of epidemiologic studies published in the 1990s. Arch Intern Med 2000, 160:2093.
38. Fries JF, Murtagh KF, Bennett M, Zatarain E, Lingala B, Bruce B The rise and decline in nonsteroidal anti-inflammatory drug-associated gastropathy in rheumatoid arthritis. Arthritis Rheum 2004, 50:2433-2440.
39. Singh G, Ramey DR NSAID-induced gastrointestinal complications: The ARAMIS perspective, 1997. J Rheumatol 1998, 25(51):8-16.
40. Hernandez-Diaz S, Rodriguez LA Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: An overview of epidemiologic studies published in the 1990s. Arch Intern Med 2000, 160:2093.
41. Silverstein FE, Graham DY, Senior JR, Davies HW, Struthers BJ, Bittman RM, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs: A randomized, doubleblind, placebo-controlled trial. Ann Intern Med 1995, 123:241-249.
42. Shorr RI, Ray WA, Daugherty JR, Griffin MR Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease. Arch Intern Med 1993, 153:1665-1670.
43. Garcia Rodriguez LA, Jick H Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal antiinflammatory drugs. Lancet 1994, 343:769-772.
44. Piper JM, Ray WA, Daugherty JR, Griffin MR Corticosteroid use and peptic ulcer disease: Role of nonsteroidal anti-inflammatory drugs. Ann Intern Med 1991, 114:735-740.
45. Hernandez-Diaz S, Rodriguez LA Steroids and risk of upper gastrointestinal complications. Am J Epidemiol 2001, 153:1089-1093.
46. Silverstein FE, Graham DY, Senior JR, Davies HW, Struthers BJ, Bittman RM, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs: A randomized, doubleblind, placebo-controlled trial. Ann Intern Med 1995, 123:241-249.
47. Chan FK, Hung LC, Suen BY, Wu JC, Lee KC, Leung VK, et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 2002, 347:2104-2110.
48. Hawkey CJ, Karrasch JA, Szczepanski L, Walker DG, Barkun A, Swannell AJ, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs: Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 1998, 338:727-734.
49. Yeomans ND, Tulassay Z, Juhasz L, Racz I, Howard JM, van Rensburg CJ, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs: Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med 1998, 338:719-726.
50. Chan FK, Hung LC, Suen BY, Wu JC, Lee KC, Leung VK, et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 2002, 347:2104-2110.
51. Bjorkman D Nonsteroidal anti-inflammatory drug-associated toxicity of the liver, lower gastrointestinal tract, and esophagus. Am J Med 1998, 105(5A):17S-21S.
52. Teoh NC, Farrell GC Hepatotoxicity associated with nonsteroidal anti-inflammatory drugs. Clinics Liver Disease 2003, 7:401-413.
53. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study, a randomized controlled trial. JAMA 2000, 284:1247-1255.
54. Davies NM Toxicity of nonsteroidal anti-inflammatory drugs in the large intestine. Dis Colon Rectum 1995, 38:1311-1321.
55. Gibson GR, Whitacre EB, Ricotti CA Colitis induced by nonsteroidal anti-inflammatory drugs: Report of four cases and review of the literature. Arch Intern Med 1992, 152:625-632.
56. Solomon DH Selective COX-2 inhibitors and cardiovascular outcomes. Arthritis Rheum 2005, 52:1968-1978.
57. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, Fitzgerald GA Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA 1999, 96:272-277.
58. FitzGerald GA, Patrono C The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001, 345:433-442.
59. Cheng Y, Austin SC, Rocca B, Koller BH, Coffman TM, Grosser T, et al. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 2002, 296:539-541.
60. Egan KM, Lawson JA, Fries S, Koller B, Rader DJ, Smyth EM, et al. COX-2-derived prostacyclin confers atheroprotection on female mice. Science 2004, 306:1954-1957.
61. Fitzgerald G Accessed 12 March 2005. 62. Chenevard R, Hurlimann D, Bechir M, et al. Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation 2003, 107:405-409. http://www.fda.gov/ohrms/dockets/ac/05/slides/2005-409051_03_FDA-Fitzger ald.ppt.
62. Widlansky ME, Price DT, Noyan G, et al. Short-and long-term COX-2 inhibition reverses endothelial dysfunction in patients with hypertension. Hypertension 2003, 42:310-315.
63. Title LM, Giddens K, Mclnerney MM, McQuenn MJ, Nassar BA Effective of cyclooxygease-2 inhibition with rofecoxib on endothelial dysfunction and inflammatory markers in patients with coronary artery disease. J Am Coll Cardiol 2003, 42:1747-1753.
64. Bogaty P, Brophy JM, Noel M, Boyer L, Simard S, Bertrand F, et al. Impact of prolonged cyclooxygenase-2 inhibition on inflammatory markers and endothelial function in patients with ischemic heart disease and raised C-reactive protein. Circulation 2004, 110:934-939.
65. Walter MF, Jacob RF, Day CA, Dahlborg R, Weng Y, Mason RP Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: Comparison to sulfonamide COX-2 inhibitors and NSAIDs. Atherosclerosis 2004, 177:235-243.
66. Gurwitz JH, Avorn J, Bohn RL, Glynn RJ, Monane M, Mogun H Initiation of antihypertensive treatment during nonsteroidal anti-inflammatory drug therapy. JAMA 1994, 272:781-786.
67. Pope JE, Anderson JJ, Felson DT A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 1993, 153:477-484.
68. Aw TJ, Haas SJ, Liew D, Krum H Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med 2005, 165:1-7.
69. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. VIGOR Study Group: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000, 343:1520-1528.
70. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005, 352:1092-1102.
71. Weir MR, Sperling RS, Reicin A, Gertz BJ Selective COX-2 inhibition and cardiovascular effects: A review of the rofecoxib development program. Am Heart J 2003, 146:591-604.
72. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study, a randomized controlled trial. JAMA 2000, 284:1247-1255.
73. Solomon SD, McMurray JV, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005, 352(11):1071-1080.
74. Accessed 10 March 2005 . http://www.fda.gov/ohrms/dockets/ac/05/briefing/20054090B1_03_Pfizer-Cel ebrex-Bextra.pdf.
75. Ott E, Nussmeier NA, Duke PC, et al. Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J Thoracic Cardiovasc Surg 2003, 125:1481-1490.
76. Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005, 352(11):1081-1091.
77. Farkouh ME, Kirshner H, Harrington RA, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes, randomized controlled trial. Lancet 2004, 364:675-684.
78. Ray WA, Stein CM, Daugherty JR, Hall K, Arbogast PG, Griffin MR COX-2 selective nonsteroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002, 360:1071-1073.
79. Solomon DH, Schneeweiss S, Glynn RJ, Kiyota Y, Levin R, Mogun H, et al. Relationship between selective COX-2 inhibitors and acute myocardial infarction. Circulation 2004, 109:2068-2073.
80. Schneeweiss S, Glynn RJ, Tsai EH, Avorn J, Solomon DH Adjusting for unmeasured confounders in pharmacoepidemiologic claims data using external information: The example of COX-2 inhibitiors and myocardial infarction. Epidemiology 2005, 16:17-24.
81. Graham DJ, Campen D, Hui R, Spence M, Cheetham C, Levy G, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: Nested case-control study. Lancet 2005, 365:475-481.
82. Kimmel SE, Berlin JA, Reilly M, Jaskowiak J, Kishel L, Chittams J, et al. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann Intern Med 2005, 142:157-164.
83. Mamdani M, Rochon P, Juurlink DN, et al. Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction. Arch Intern Med 2003, 163:481-486.
84. Shaya FT, Blume SW, Blanchette CM, Weir MR, Mullins CD Selective cyclooxygenase-2 inhibition and cardiovascular effects. Arch Intern Med 2005, 165:181-186.
85. Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001, 345:1809-1817.
86. MacDonald TM, Wei L Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 2003, 361:573-574.
87. Kimmel SE, Berlin JA, Reilly M, Jaskowiak J, Kishel L, Chittams J, et al. The effects of nonselective non-aspirin non-steroidal anti-inflammatory medications on the risk of nonfatal myocardial infarction and their interaction with aspirin. J Am Coll Cardiol 2004, 43:985-990.
88. Kurth T, Glynn RJ, Walker AM, Chan KA, Buring JE, Hennekens CH, et al. Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs. Circulation 2003, 108:1191-1195.
89. Curtis JP, Wang YF, Portnay EL, Masoudi FA, Havranek EP, Krumholz HM Aspirin, ibuprofen, and mortality after myocardial infarction: Retrospective cohort study. Br Med J 2003, 327:1322-1323.
90. Patel TN, Goldberg KC Use of aspirin and ibuprofen compared with aspirin alone and the risk of myocardial infarction. Arch Intern Med 2004, 164:852-856.
91. Garcia Rodriguez LA, Varas-Lorenzo C, Maguire A, Gonzalez-Perez A Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the general population. Circulation 2004, 109:3000-3006.
92. Solomon DH, Goodson NJ The cardiovascular system in rheumatic disease: The next "extra-articular" manifestation?. J Rheumatol 2005, 32:1415-1418.
93. Swan SK, Rudy DW, Lasseter KC, Ryan CF, Buechel KL, Lambrecht LJ, et al. Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet: A randomized, controlled trial. Ann Intern Med 2000, 133(1):1-9.
94. Rossat J, Maillard M, Nussberger J, Brunner HR, Burnier M Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin Pharmacol Ther 1999, 66:76-84.
95. Catella-Lawson F, McAdam B, Morrison BW, Kapoor S, Kujubu D, Antes L, et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol & Exp Ther 1999, 289(2):735-741.
96. Griffin MR, Yared A, Ray WA Nonsteroidal antiinflammatory drugs and acute renal failure in elderly persons. Am J Epidemiol 2000, 151(5):488-496.
97. Perez Gutthann S, Garcia Rodriguez LA, Raiford DS, Duque Oliart A, Ris Romeu J Nonsteroidal anti-inflammatory drugs and the risk of hospitalization for acute renal failure. Arch Intern Med 1996, 156(21):2433-2439.
98. Perneger TV, Whelton PK, Klag MJ Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal antiinflammatory drugs. N Engl J Med 1994, 331(25):1675-1679.
99. Sandler DP, Burr FR, Weinberg CR Nonsteroidal anti-inflammatory drugs and the risk for chronic renal disease. Ann Intern Med 1991, 115(3):165-172.
100. Alanko K, Stubb S, Kauppinen K Cutaneous drug reactions: Clinical types and causative agents. A five-year survey of in-patients (1981-1985). Acta Dermato-Venereologica 1989, 69(3):223-226.
101. Accessed 29 July 2005 . http://www.fda.gov/cder/drug/infopage/COX2/default.htm.
102. Curhan GC, Bullock AJ, Hankinson SE, Willett WC, Speizer FE, Stampfer MJ Frequency of use of acetaminophen, nonsteroidal anti-inflammatory drugs, and aspirin in US women. Pharmacoepidemiol Drug Safety 2002, 11:687-693.
103. Solomon DH, Schneeweiss S, Glynn RJ, Levin R, Avorn J Determinants of selective cyclooxygenase-2 inhibitor prescribing: Are patient or physician characteristics more important?. Am J Med 2003, 115(9):715-720.
104. Dai C, Stafford RS, Alexander GC National trends in cyclooxygenase-2 inhibitor use since market release: Nonselective diffusion of a selectively cost-effective innovation. Arch Intern Med 2005, 165(2):171-177.
105. Solomon DH, Schneeweiss S, Glynn RJ, Levin R, Avorn J Determinants of selective cyclooxygenase-2 inhibitor prescribing: Are patient or physician characteristics more important?. Am J Med 2003, 115(9):715-720.
106. Patino FG, Allison J, Olivieri J, Mudano A, Juarez L, Person S, et al. The effects of physician specialty and patient comorbidities on the use and discontinuation of coxibs. Arthritis Rheum 2003, 49(3):293-299.
107. Greenberg JD, Bingham CO, Abramson SB, Reed G, Sebaldt RJ, Kremer J Effect of cardiovascular comorbidities and concomitant aspirin use on selection of cyclooxygenase inhibitor among rheumatologists. Arthritis Rheum 2005, 53(1):12-17.
108. Smalley W, Stein CM, Arbogast PG, Eisen G, Ray WA, Griffin M Underutilization of gastroprotective measures in patients receiving nonsteroidal antiinflammatory drugs. Arthritis Rheum 2002, 46(8):2195-2200.
109. Solomon DH, Schneeweiss S, Glynn RJ, Levin R, Avorn J Determinants of selective cyclooxygenase-2 inhibitor prescribing: Are patient or physician characteristics more important?. Am J Med 2003, 115(9):715-720.
110. Spiegel BM, Targownik L, Dulai GS, Gralnek IM The costeffectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis. Ann Intern Med 2003, 138(10):795-806.
111. Maetzel A, Krahn M, Naglie G The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis. Arthritis Rheum 2003, 49(3):283-292.
112. Smalley W, Stein CM, Arbogast PG, Eisen G, Ray WA, Griffin M Underutilization of gastroprotective measures in patients receiving nonsteroidal antiinflammatory drugs. Arthritis Rheum 2002, 46(8):2195-2200.
113. Stein CM, Griffin MR, Taylor JA, Pichert JW, Brandt KD, Ray WA Educational program for nursing home physicians and staff to reduce use of non-steroidal anti-inflammatory drugs among nursing home residents: A randomized controlled trial. Medical Care 2001, 39(5):436-445.